Dolutegravir for COVID-19: real-time analysis of 2 studies

Download Image

Post

c19early.org

Dolutegravir for COVID-19

2 studies with >1,000 patients

Serious outcome risk

Dolutegravir

Control

No significant improvements are seen in meta-analysis to date.

COVID-19 Dolutegravir studies · October 2026

Outcome (studies)

Improvement

Relative risk · 95% CI

All studies (2)−15%

Mortality (1)−202%

Cases (1)−20%

RCTs (1)−202%

Prophylaxis (1)−14%

Late (1)−202%

00.511.5+

← Dolutegravir
reduces riskIncreased
risk →

.hmva--anim-stagger .hmva__row{opacity:1}.hmva--anim .hmva__shade{opacity:var(--shade-opacity)}.hmva--anim-stagger .est .ci{transform:translateY(-50%)}.hmva--anim-stagger .est .pt{transform:translate(-50%,-50%)}.hmva--anim-stagger .hmva__bar{transform:none}.hmva--anim-settle .est .pt{left:calc(min(var(--pt), 1.5) / var(--max) * 100%)}.hmva--anim-settle .est .ci{left:calc(var(--lo) / var(--max) * 100%);width:calc((var(--hi) - var(--lo)) / var(--max) * 100%)}.hmva--anim-settle .hmva__bar--drug{width:calc(min(1, var(--rr)) * 100%)}.hmva--anim-settle .hmva__bar--control{width:calc(min(1, 1 / var(--rr)) * 100%)}


	Covid Analysis	Meta-analysis of dolutegravir studies
	Meta-analysis of dolutegravir studies
Jun 26 2024	Abbaspour Kasgari et al., BioImpacts, doi:10.34172/bi.29952	Effectiveness of dolutegravir in moderate severity COVID-19 patients: A single-center, randomized, double-blind, placebo-controlled trial
	202% higher mortality (p=0.49) and 5% lower need for oxygen therapy (p=1). RCT 93 hospitalized patients with moderate COVID-19 showing no significant difference in clinical outcomes with dolutegravir treatment compared to placebo.
Apr 13 2023	Verburgh et al., AIDS, doi:10.1097/QAD.0000000000003577	No association between use of tenofovir disoproxil fumarate, etravirine, or integrase-strand transfer inhibitors and acquisition or severe outcomes of SARS-CoV-2 infection in people with HIV in the Netherlands
	14% higher combined mortality/hospitalization (p=0.54) and 20% more cases (p=0.75). Analysis of two Dutch cohorts with HIV showing no association between tenofovir disoproxil fumarate (TDF), etravirine (ETR), or integrase-strand transfer inhibitors (INSTIs) use and either the risk of incident SARS-CoV-2 infection or seve..